Released: September 14, 2022
Recorded: August 30, 2022
Expiration date: September 15, 2025
There is increasing recognition of neural antibodies and autoimmune disorders as a potential cause of seizures in patients with unexplained epilepsy. This webinar will discuss various diagnostic approaches, including cerebrospinal fluid analysis, neuroimaging, autoantibody testing, and will provide you with some practical diagnostic tips on using them in your epilepsy patients. There will be ample opportunity to ask questions and share real-world experiences with an expert.
Dr. Claude Steriade, MD, CM
New York University Langone Health
Ohio State University Wexner Medical Center
At the end of this webinar, attendees should be able to:
- Discuss the stepwise approach to the diagnosis of autoimmune epilepsy and use of predictive scoring models
- Interpret neural antibodies panel testing, significance of low positive titer (e.g. GAD-65, TPO Abs) or presence of antibodies with unknown clinical significance
- Determine the approach to seronegative autoimmune epilepsy cases
It is the policy of the American Epilepsy Society (AES) to ensure balance, independence, objectivity and scientific rigor. All individuals involved in the selection, development and presentation of content are required to disclose any real or apparent conflicts of interest. Conflicts of interest will be resolved by AES prior to an educational activity being delivered to learners.
Planning Committee, Faculty, Reviewers' Disclosures of Financial Relationships
In accordance with the ACCME Standards for Commercial Support, the AES requires that any person who is in a position to control content of a CME activity must disclose all relevant financial relationships that they have with a commercial interest. Unless otherwise indicated (*), none of the planners or faculty of this activity have any financial relationships to disclose. All relevant financial relationships with commercial interests have been mitigated. The following individuals contributed to this activity’s content.
Planning Committee and Faculty
Claude Steriade, MD, CM
David Ficker, MD-Consultant/Other: Greenwich Pharmaceutical, Best Doctors, Verana Health
Madison Berl, PhD-Consultant: Cadence Design Systems, Praxis Precision medicines, Encoded Therapeutics
Jeannine Conway, PharmD-Consultant: Greenwich Biosciences
Tyler Gaston, MD-Consultant: Greenwich Biosciences, Inc.
Soundarya N. Gowda, MD
Nicole Hartmann, DO, MBS
Elaine Kiriakopoulos, MD, MSc
Liu Lynn, MD
Wolfgang Muhlhofer, MD
Madona Plueger, ACNS-BC, APRN, CNRN, FAES
Olga Selioutski, DO-Grant/Contract: SAGE, UCB Inc.
Jaysingh Singh, MD
Chengyuan Wu, MD
Ika Noviawaty, MD
American Epilepsy Society Staff Planners
Kandice Kidd, MA
Resolution of Conflicts of Interest
It is the policy of the American Epilepsy Society to ensure balance, independence, objectivity and scientific rigor. All persons involved in the selection, development and presentation of content are required to disclose any real or apparent conflicts of interest. In accordance with the ACCME Standards for Commercial Support of CME, the AES implemented the mechanisms of prospective peer review of this CME activity, to identify and resolve any conflicts. Additionally, the content of this activity is based on the best available evidence.
The American Epilepsy Society is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
For more information regarding contact hours, please call American Epilepsy Society 312.883.3800 or firstname.lastname@example.org.
The American Epilepsy Society designates this enduring activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
To receive credit for your participation in this activity, please complete the evaluation survey provided at the conclusion of the activity.
Unapproved Use Disclosure
The American Epilepsy Society requires CME authors to disclose to learners when products or procedures being discussed are off-label, unlabeled, experimental, and/or investigational (not FDA approved); and any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. If you have questions, contact the medical affairs department of the manufacturer for the most recent prescribing information. Information about pharmaceutical agents/devices that is outside of U.S. Food and Drug Administration approved labeling may be contained in this activity.
This CME activity is for educational purposes only and does not constitute the opinion or endorsement of, or promotion by, the American Epilepsy Society. Reasonable efforts have been taken to present educational subject matter in a balanced, unbiased fashion, and in compliance with regulatory requirements. However, each activity participant must always use his or her own personal and professional judgment when considering further application of this information, particularly as it may relate to patient diagnostic or treatment decisions including, without limitation, FDA-approved uses and any off-label, investigational and/or experimental uses.